巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    虛擬市場

    BioRestorative Therapies

    BRTX
    3.510
    ▲0.310
    ▲9.69%
    概況消息
    最少15分鐘延遲，股票資訊由第三方資訊供應商提供
    ・BioRestorative Therapies - 延遲價格・最後更新於 28/06 9:03
    最高位
    3.510
    最低位
    3.510
    開市價
    --
    前收市價
    3.200
    成交量(千)
    0.10
    成交額(百萬)
    0.00
    買入
    2.630
    賣出
    4.320
    每手股數
    --
    市值(百萬)
    12.77
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    25,000.000 - 0.002
    所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    BioRestorative Therapies
    證券代碼
    BRTX.US
    所屬板塊
    Biotechnology
    公司業務
    BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
    發行量
    3637594
    公司總部
    40 Marcus Drive, Suite One
    公司網址
    https://www.biorestorative.com
    公司電話
    +1 631 760-8100

    最新發佈

    暫無內容

    關於

    BioRestorative Therapies(BRTX.US)所屬的行業板塊為Biotechnology。
    BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
    詳細公司背景可參考: https://www.biorestorative.com。